瑞舒伐他汀对PCI患者术后脂联素和高敏C反应蛋白的影响(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 观察瑞舒伐他汀对经皮冠状动脉介入治疗(PCI)术后高敏C反应蛋白(hs-CRP)和脂联素(APN)的影响。 方法 选择在我院行PCI的120例患者为研究对象，将其随机分为阿托伐他汀组(40例)、低瑞舒伐他组(37例)和高瑞舒伐他组(43例)。在常规治疗的基础上，在PCI术前7 d开始给予阿托伐他汀或瑞舒伐他汀治疗。分别于术前、术后1 d、术后1周及术后4周采集患者空腹静脉血，测定血清hs-CRP和血清脂联素(APN)浓度；术前检测血脂浓度。 结果 PCI术前三组间血脂总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)水平和高密度脂蛋白(HDL-C)水平差异无统计学意义；PCI术前三组间的APN和hs-CRP浓度比较，差异无统计学意义(P > 0.05)。PCI术后1周和术后4周时，与阿托伐他汀组相比，低瑞舒伐他汀组APN浓度升高，hs-CRP浓度降低，但差异无统计学意义(P > 0.05)；而高瑞舒伐他汀组较阿托伐他汀组和低瑞舒伐他汀组APN浓度升高更明显，hs-CRP浓度降低更明显(P < 0.05)。 结论 早期应用瑞舒伐他汀可明显降低PCI术后血清hs-CRP水平和升高APN水平，且效果优于阿托伐他汀。
[关键词] 瑞舒伐他汀；经皮冠状动脉介入治疗；脂联素；高敏C反应蛋白
[中图分类号] R96 [文献标识码] A [文章编号] 1673-7210(2012)02(b)-0069-03
Effect of Rosuvastatin on hs-CRP and APN level in patients after percrtaneous coronary intervention
ZOU Yong1,2 YANG Tianlun1 PU Xiaoqun1 LI Chuanchang1 XIE Qiying1 XU Xiping2
1.Department of Cardiovascular, the First Affiliated Hospital of Xiangya School of Medicine, Central South University, Hu'nan Province, Changsha 410008, China; 2.Department of Cardiovascular, the First People's Hospital of Yueyang City, Hu'nan Province, Yueyang 414000, China
[Abstract] Objective To investigate the effect of Rosvastatin on serum high sensitive C-reactive protein (hs-CRP) and adiponectin (APN) in patients after percutaneous coronary intervention (PCI). Methods This study included 120 patients with PCI, who were randomly divided into Atorvastatin treatment group, low Rosvastatin treatment group and high Rosvastatin treatment group. For those treatment group, Rosvastatin or Atorvastatin was added, starting from 7 days before PCI. The serum hs-CRP and APN were measured on admission, before and 1 day, 1 week as well as 4 weeks after PCI. Lipids were measured before PCI. Results The differences of hs-CRP, APN and lipids between the three groups were not significant different before PCI (P > 0.05). Postoperatively for 1 week and 4 weeks, the level of hs-CRP was decreased, and APN was increased in the low Rosvastatin treatment group compared with Atorvastatin group (P > 0.05). The level of hs-CRP was decreased more significantly, and APN elevated more significantly in the high Rosvastatin treatment group compared with Atorvastatin group or low Rosvastatin group (P < 0 ......
您现在查看是摘要介绍页，详见PDF附件(2920kb)。